if the 5 SCI patient trial of the scaffolds is successful (all indications are they will be)--would this expediate a "takeover"? I keep hearing that Stryker and Johnson and Johnson are "kicking the tires" concerning In Vivo---if this is the case would In Vivo quickly sell to the "highest bidder" and if a takeover is "hinted at" would this run up to the potential buyout cause the pps to rise higher than what is forecasted ($8-$10)?
Frank has said on at least two occasions that the SCI market could easily be served with 20 NVIV sales people and they could manufacture in house all the scaffold needed to meet that market. He indicates NVIV would keep that market entirely to themselves.
The periferal nerve market would need a much bigger sales effort and therefore partnering that would make sense.
Frank has mentioned numerous times the possibility of partnering with a device manufacturer to produce the products. I believe NVIV plans to do so with the scaffold once FDA gives approval in order to generate funding for the next product in the pipeline.